New Dyslipidemia Post-ACC.19 Content

The ACC.19 Meeting Coverage Page on now features post-meeting content on dyslipidemia to reinforce the teaching points and education presented during ACC.19. In one expert analysis, Robert Derenbecker, MD, et al., analyzed results from the REDUCE-IT trial, which found that icosapent ethyl significantly reduces total ischemic events in patients with cardiovascular risk factors, including elevated triglycerides, who are on statins. In another expert analysis, Jessica Mao, MD, et al., analyzed results from the CLEAR Wisdom, noting how CLEAR Wisdom identified percent change in LDL-C as its primary outcome measure, while CLEAR Harmony listed this as a secondary outcome measure with a primary outcome measure of enumerating treatment-related adverse events. View additional learning pathway presentations in iScience, the ACC.19 Meeting on Demand™ Program. Stay tuned as more content will be added to the ACC.19 Meeting Coverage Page in the coming months.